Copyright Reports & Markets. All rights reserved.

Cancer Drugs-Global Market Status and Trend Report 2015-2026

Buy now

Table of Contents

    Chapter 1 Overview of Cancer Drugs

    • 1.1 Definition of Cancer Drugs in This Report
    • 1.2 Commercial Types of Cancer Drugs
      • 1.2.1 Chemotherapy
      • 1.2.2 Targeted Therapy
      • 1.2.3 Immunotherapy
      • 1.2.4 Hormonal Therapy (Biologic Therapy)
      • 1.2.5 Others
    • 1.3 Downstream Application of Cancer Drugs
      • 1.3.1 Blood Cancer
      • 1.3.2 Breast Cancer
      • 1.3.3 Gastrointestinal Cancer
      • 1.3.4 Prostate Cancer
      • 1.3.5 Respiratory/Lung Cancer
      • 1.3.6 Other Cancers
    • 1.4 Development History of Cancer Drugs
    • 1.5 Market Status and Trend of Cancer Drugs 2015-2026
      • 1.5.1 Global Cancer Drugs Market Status and Trend 2015-2026
      • 1.5.2 Regional Cancer Drugs Market Status and Trend 2015-2026

    Chapter 2 Global Market Status and Forecast by Regions

    • 2.1 Market Development of Cancer Drugs 2015-2019
    • 2.2 Production Market of Cancer Drugs by Regions
      • 2.2.1 Production Volume of Cancer Drugs by Regions
      • 2.2.2 Production Value of Cancer Drugs by Regions
    • 2.3 Demand Market of Cancer Drugs by Regions
    • 2.4 Production and Demand Status of Cancer Drugs by Regions
      • 2.4.1 Production and Demand Status of Cancer Drugs by Regions 2015-2019
      • 2.4.2 Import and Export Status of Cancer Drugs by Regions 2015-2019

    Chapter 3 Global Market Status and Forecast by Types

    • 3.1 Production Volume of Cancer Drugs by Types
    • 3.2 Production Value of Cancer Drugs by Types
    • 3.3 Market Forecast of Cancer Drugs by Types

    Chapter 4 Global Market Status and Forecast by Downstream Industry

    • 4.1 Demand Volume of Cancer Drugs by Downstream Industry
    • 4.2 Market Forecast of Cancer Drugs by Downstream Industry

    Chapter 5 Market Driving Factor Analysis of Cancer Drugs

    • 5.1 Global Economy Situation and Trend Overview
    • 5.2 Cancer Drugs Downstream Industry Situation and Trend Overview

    Chapter 6 Cancer Drugs Market Competition Status by Major Manufacturers

    • 6.1 Production Volume of Cancer Drugs by Major Manufacturers
    • 6.2 Production Value of Cancer Drugs by Major Manufacturers
    • 6.3 Basic Information of Cancer Drugs by Major Manufacturers
      • 6.3.1 Headquarters Location and Established Time of Cancer Drugs Major Manufacturer
      • 6.3.2 Employees and Revenue Level of Cancer Drugs Major Manufacturer
    • 6.4 Market Competition News and Trend
      • 6.4.1 Merger, Consolidation or Acquisition News
      • 6.4.2 Investment or Disinvestment News
      • 6.4.3 New Product Development and Launch

    Chapter 7 Cancer Drugs Major Manufacturers Introduction and Market Data

    • 7.1 Roche
      • 7.1.1 Company profile
      • 7.1.2 Representative Cancer Drugs Product
      • 7.1.3 Cancer Drugs Sales, Revenue, Price and Gross Margin of Roche
    • 7.2 Takeda
      • 7.2.1 Company profile
      • 7.2.2 Representative Cancer Drugs Product
      • 7.2.3 Cancer Drugs Sales, Revenue, Price and Gross Margin of Takeda
    • 7.3 Bristol-Myers Squibb
      • 7.3.1 Company profile
      • 7.3.2 Representative Cancer Drugs Product
      • 7.3.3 Cancer Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
    • 7.4 Novartis
      • 7.4.1 Company profile
      • 7.4.2 Representative Cancer Drugs Product
      • 7.4.3 Cancer Drugs Sales, Revenue, Price and Gross Margin of Novartis
    • 7.5 Pfizer
      • 7.5.1 Company profile
      • 7.5.2 Representative Cancer Drugs Product
      • 7.5.3 Cancer Drugs Sales, Revenue, Price and Gross Margin of Pfizer
    • 7.6 Celgene
      • 7.6.1 Company profile
      • 7.6.2 Representative Cancer Drugs Product
      • 7.6.3 Cancer Drugs Sales, Revenue, Price and Gross Margin of Celgene
    • 7.7 AstraZeneca
      • 7.7.1 Company profile
      • 7.7.2 Representative Cancer Drugs Product
      • 7.7.3 Cancer Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
    • 7.8 Johnson & Johnson
      • 7.8.1 Company profile
      • 7.8.2 Representative Cancer Drugs Product
      • 7.8.3 Cancer Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
    • 7.9 Amgen
      • 7.9.1 Company profile
      • 7.9.2 Representative Cancer Drugs Product
      • 7.9.3 Cancer Drugs Sales, Revenue, Price and Gross Margin of Amgen
    • 7.10 Eli Lilly
      • 7.10.1 Company profile
      • 7.10.2 Representative Cancer Drugs Product
      • 7.10.3 Cancer Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
    • 7.11 Biogen Idec
      • 7.11.1 Company profile
      • 7.11.2 Representative Cancer Drugs Product
      • 7.11.3 Cancer Drugs Sales, Revenue, Price and Gross Margin of Biogen Idec
    • 7.12 Otsuka
      • 7.12.1 Company profile
      • 7.12.2 Representative Cancer Drugs Product
      • 7.12.3 Cancer Drugs Sales, Revenue, Price and Gross Margin of Otsuka
    • 7.13 Astellas
      • 7.13.1 Company profile
      • 7.13.2 Representative Cancer Drugs Product
      • 7.13.3 Cancer Drugs Sales, Revenue, Price and Gross Margin of Astellas
    • 7.14 Ipsen
      • 7.14.1 Company profile
      • 7.14.2 Representative Cancer Drugs Product
      • 7.14.3 Cancer Drugs Sales, Revenue, Price and Gross Margin of Ipsen
    • 7.15 Eisai
      • 7.15.1 Company profile
      • 7.15.2 Representative Cancer Drugs Product
      • 7.15.3 Cancer Drugs Sales, Revenue, Price and Gross Margin of Eisai
    • 7.16 Bayer
    • 7.17 Merck & Co.
    • 7.18 Merck KGaA
    • 7.19 Teva
    • 7.20 Sanofi
    • 7.21 AbbVie
    • 7.22 Gilead Sciences

    Chapter 8 Upstream and Downstream Market Analysis of Cancer Drugs

    • 8.1 Industry Chain of Cancer Drugs
    • 8.2 Upstream Market and Representative Companies Analysis
    • 8.3 Downstream Market and Representative Companies Analysis

    Chapter 9 Cost and Gross Margin Analysis of Cancer Drugs

    • 9.1 Cost Structure Analysis of Cancer Drugs
    • 9.2 Raw Materials Cost Analysis of Cancer Drugs
    • 9.3 Labor Cost Analysis of Cancer Drugs
    • 9.4 Manufacturing Expenses Analysis of Cancer Drugs

    Chapter 10 Marketing Status Analysis of Cancer Drugs

    • 10.1 Marketing Channel
      • 10.1.1 Direct Marketing
      • 10.1.2 Indirect Marketing
      • 10.1.3 Marketing Channel Development Trend
    • 10.2 Market Positioning
      • 10.2.1 Pricing Strategy
      • 10.2.2 Brand Strategy
      • 10.2.3 Target Client
    • 10.3 Distributors/Traders List

    Chapter 11 Report Conclusion

      Chapter 12 Research Methodology and Reference

      • 12.1 Methodology/Research Approach
        • 12.1.1 Research Programs/Design
        • 12.1.2 Market Size Estimation
        • 12.1.3 Market Breakdown and Data Triangulation
      • 12.2 Data Source
        • 12.2.1 Secondary Sources
        • 12.2.2 Primary Sources

      Report Summary

      Cancer Drugs-Global Market Status and Trend Report 2015-2026 offers a comprehensive analysis on Cancer Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

      Worldwide and Regional Market Size of Cancer Drugs 2015-2019, and development forecast 2020-2026
      Main manufacturers/suppliers of Cancer Drugs worldwide, with company and product introduction, position in the Cancer Drugs market
      Market status and development trend of Cancer Drugs by types and applications
      Cost and profit status of Cancer Drugs, and marketing status
      Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Cancer Drugs market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Cancer Drugs industry.

      The report segments the global Cancer Drugs market as:

      Global Cancer Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2015-2026):
      North America
      Europe
      China
      Japan
      Rest APAC
      Latin America

      Global Cancer Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2015-2026):
      Chemotherapy
      Targeted Therapy
      Immunotherapy
      Hormonal Therapy (Biologic Therapy)
      Others

      Global Cancer Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2015-2026; Downstream Customers and Market Analysis)
      Blood Cancer
      Breast Cancer
      Gastrointestinal Cancer
      Prostate Cancer
      Respiratory/Lung Cancer
      Other Cancers

      Global Cancer Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Cancer Drugs Sales Volume, Revenue, Price and Gross Margin):
      Roche
      Takeda
      Bristol-Myers Squibb
      Novartis
      Pfizer
      Celgene
      AstraZeneca
      Johnson & Johnson
      Amgen
      Eli Lilly
      Biogen Idec
      Otsuka
      Astellas
      Ipsen
      Eisai
      Bayer
      Merck & Co.
      Merck KGaA
      Teva
      Sanofi
      AbbVie
      Gilead Sciences

      In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

      Buy now